Logotype for biote Corp

biote (BTMD) Q3 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for biote Corp

Q3 2024 earnings summary

14 Jan, 2026

Executive summary

  • Q3 2024 revenue increased 12.8% year-over-year to $51.4 million, driven by growth in procedures and dietary supplements, with strong Amazon channel performance.

  • Adjusted EBITDA rose to $16.2 million (31.5% margin), up from $14.0 million (30.8% margin) in Q3 2023.

  • Net income for Q3 2024 was $12.7 million, with diluted EPS of $0.33, impacted by fair value changes in earnout liabilities and higher interest expense.

  • Strategic acquisitions in 2024, including Asteria Health, Simpatra, and BioSana, enhanced vertical integration, supply chain control, and manufacturing capabilities.

  • Launched enhanced clinical decision support software, expanding treatment options and patient reach, but causing temporary workflow disruptions impacting procedure volumes.

Financial highlights

  • Q3 2024 revenue: $51.4 million (+12.8% YoY); procedure revenue grew 7.1%, dietary supplement revenue up 21.7%.

  • Gross profit margin improved to 70.5% (up from 68.9% YoY), reflecting cost savings from vertical integration.

  • Operating income rose to $12.2 million from $7.6 million YoY; net income included a $7.2 million gain from earnout liability revaluation.

  • Cash and cash equivalents at quarter-end were $38.2 million, up from $26.4 million at the end of Q2 2024.

  • Year-to-date cash flow from operations: $32.9 million, up from $19.9 million for the same period in 2023.

Outlook and guidance

  • 2024 revenue guidance revised to $197–$201 million and adjusted EBITDA to $58–$61 million, down from previous guidance due to software transition and hurricane-related clinic closures.

  • Expect continued growth from top-tier accounts, network expansion, and dietary supplement sales in Q4 2024.

  • Anticipate procedure revenue growth to re-accelerate in 2025 as workflow disruptions subside.

  • Company believes current cash, operations, and revolving loan capacity are sufficient for at least the next 12 months.

  • Ongoing focus on cost savings from vertical integration and margin improvement.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more